The purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12
Drug: IV granisetron
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01596413
Ages eligible for Study
6 Years to 12 Years
Genders eligible for Study
Accepts Healthy Volunteers
6 to 12 years of age inclusive at screening.
Written patient or parental (or appropriate legal representative) IRB approved informed consent as appropriate.
Written patient assent (as appropriate).
Scheduled to receive 2 or more cycles* of emetogenic chemotherapy requiring 5-HT3 antagonist treatment.
Scheduled to receive one or more consecutive days of 5-HT3 antagonist treatment, per cycle, as CINV prophylaxis.
The cycles of chemotherapy must be consecutive (i.e. one followed by the other) but do not have to be the first and second cycle of a line of treatment.
Hypersensitivities, allergies or contraindications to study medications; intolerance of medical tape or sticking plaster.
Clinical or laboratory signs and symptoms of significant cerebral, cardiovascular, respiratory, renal, hepatobiliary, pancreatic or infectious disease, which in the Investigator's judgment may interfere with the study assessment or completion of the study.
Patients with a known history or predisposition to cardiac conduction interval abnormalities, including QT Syndrome, or known family history of long QT Syndrome or taking medications that are known to prolong the QT interval.
Patients scheduled to have routine surgery during the study duration.
Patients with a life expectancy of < 6 months.
Scarring or significant skin disease on both upper arms.
Female patients who are pregnant or breast-feeding. All post menarche female patients must have a pregnancy test at screening.
Patients who are known or thought to be sexually active must use effective birth control.**
Administration of other investigational drugs within 30 days preceding the screening visit, except for anticancer treatments.
Any conditions associated with non-compliance.
Effective birth control includes absolute abstinence or double barrier birth control methods i.e. condom and one of the following: combined oral contraceptive, diaphragm, depot contraceptive injection.
All locations for NCT01596413
View full eligibility
Tris trial is registered with FDA with number: NCT01596413. The sponsor of the trial is Kyowa Kirin Pharmaceutical Development Ltd and it is looking for 16 volunteers for the current phase.
Official trial title: An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 6 to 12 Years)
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.